Dishman Carbogen Amcis Limited has scheduled a board meeting for December 27 to discuss funding through Non-Convertible Debentures (NCDs). The meeting will focus on evaluating this debt financing option as part of the pharmaceutical company's capital structure planning. This represents a significant corporate development as the company explores alternative funding mechanisms while maintaining proper corporate governance procedures.
Dishman Carbogen Amcis Schedules Board Meeting on December 27 to Discuss NCD Funding
